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Abstract
Introduction: Valoctocogene roxaparvovec is an investigational AAV5-based factor
VIII (FVIII) gene therapy thathasdemonstrated sustainedclinical benefit in peoplewith
severe haemophilia A.
Aim: To report safety, tolerability, efficacy, and quality of life (QOL) among par-
ticipants who received valoctocogene roxaparvovec in a phase 1/2 clinical study
(NCT02576795).
Methods: Men ≥18 years of age with severe haemophilia A (FVIII ≤1 IU/dl) without
history of FVIII inhibitors or anti-AAV5 antibodies received a single infusion of valoc-
tocogene roxaparvovec and were followed for 5 years (6 × 1013 vg/kg dose, n= 7) and
4 years (4× 1013 vg/kg dose, n= 6).
Results: Over the past 2 years, few adverse events and no FVIII inhibitors were
reported. Per chromogenic substrate (CSA) assay at years 5 and 4, four of seven and
three of six participants in the 6 × 1013 and 4 × 1013 vg/kg cohorts, respectively, main-
tained median FVIII levels >5 IU/dl, corresponding to mild haemophilia. By regression
analysis, rate of change in FVIII activity was -0.14 (95% confidence interval [CI]: -.32
to .03) IU/dl/wk in the 6 × 1013 vg/kg cohort in year 5 and -.06 (95% CI: -.14 to .01)
IU/dl/wk in the 4 × 1013 vg/kg cohort in year 4. No participants resumed FVIII prophy-
laxis, and eight of 13 participants reported zero bleeds in the past 2 years. Improved
QOL frombaselinepersisted in the6×1013 vg/kg cohort; all sixHaemo-QOL-Adomain
scores increased. For the 4 × 1013 vg/kg cohort, high baseline Haemo-QOL-A scores
persisted.
Conclusion: These results demonstrate transgene expression and haemostatic
response for up to 5 years in individuals with haemophilia A.
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1 INTRODUCTION
Standard of care for people with severe haemophilia A is prophylactic
administration of exogenous factor VIII (FVIII) or emicizumab to
reduce frequency of bleeding.1,2 However, some people with severe
haemophilia A on prophylaxis still experience bleeding.3,4 By eliminat-
ing peaks and troughs associated with exogenous FVIII, gene therapy
may transform treatment options and yield improved clinical outcomes
for severe haemophilia A.
Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) is an adeno-
associated virus serotype 5 (AAV5) vector encoding a B-
domain–deleted human FVIII coding sequence (hFVIII-SQ) with a
hepatocyte-selective promoter.5–7 In an ongoing phase 1/2 study
(NCT02576795), an infusion of AAV5-hFVIII-SQ in 13 adults with
severe haemophilia A at 6 × 1013 or 4 × 1013 vg/kg substantially
reduced bleeding and eliminated prophylactic exogenous FVIII use for
up to 3 years.5,6 The most common adverse event (AE) was transient,
asymptomatic increases in alanine aminotransferase (ALT).5,6 We
present updated results from this phase 1/2 study, assessing safety,
efficacy, and quality of life (QOL) from the 6 × 1013 vg/kg cohort (n
= 7) through 5 years and the 4 × 1013 vg/kg cohort (n = 6) through
4 years.
2 MATERIALS AND METHODS
2.1 Study design and participants
Primary objectives of this phase 1/2 dose-escalation study were to
assess safety of valoctocogene roxaparvovec and determine the dose
required to achieve FVIII activity ≥5 IU/dl at 16 weeks. Secondary
objectives were to assess immune responses, exogenous FVIII utilisa-
tion, and annualised treated bleeding rate. Participant QOL was eval-
uatedwith the haemophilia-specific health-relatedQOL questionnaire
for adults (Haemo-QOL-A).8–12
As previously published, eligible participantsweremen≥18 years of
age with severe haemophilia A (FVIII ≤1 IU/dl) without history of FVIII
inhibitors (and ≥150 days of exposure to FVIII concentrates or cryo-
precipitate) and without anti-AAV5 antibodies.5,6,13 Key exclusion cri-
teria included significant liver dysfunction, significant liver fibrosis, and
liver cirrhosis. Participants received one infusion of valoctocogene rox-
aparvovec.
2.2 Vector construct
The recombinant, replication-incompetent AAV5 vector contains a
hepatocyte-selective promoter, B-domain-deleted human FVIII coding
sequence (SQ-hFVIII), and synthetic polyadenylation sequence.5–7
The vector is manufactured with a baculovirus—Spodoptera
frugiperda (Sf9) insect-cell production system,14 as described
previously.5
2.3 Procedures
Participants received AAV5-hFVIII-SQ doses as follows: Participant
one received 6 × 1012 vg/kg, participant two received 2 × 1013
vg/kg, participants three through nine received 6 × 1013 vg/kg, and
participants 10–15 received 4 × 1013 vg/kg. The 4 × 1013 vg/kg dose
was selected after some participants who received 6 × 1013 vg/kg
expressed circulating FVIII above normal during year 1. As previously
described, per-protocol prophylactic glucocorticoids were adminis-
tered to participants four through nine following ALT elevation and
glucocorticoid initiation postinfusion in participant three; following
a protocol amendment, participants 10–15 only received glucocorti-
coids in response to ALT elevation (Table S1).5,6 After 1 year, partic-
ipants could enrol in a liver biopsy substudy, which required a liver
ultrasound and participants to be brought to FVIII activity>50 IU/dl.
2.4 Assessments
Safety was assessed with physical examination, laboratory assess-
ments, andAEs gradedwithCommonTerminologyCriteria forAdverse
Events v4.0.3. FVIII activity assays were performed at a central labora-
tory (Esoterix, Englewood, CO,USA) using both chromogenic substrate
(CSA) and one-stage clotting assays (OSA), as previously reported.5,6
Annualised bleeding rate (ABR) and annualised exogenous FVIII infu-
sion rate were calculated as previously described.5,6 Baseline ABR
and FVIII infusion rate were based on the 12 months prior to enrol-
ment. QOLwas evaluatedwith theHaemo-QOL-A questionnaire, com-
prising 41 items scored on a 6-point Likert-type scale grouped into
six domains: Consequences of Bleeding (7 items), Emotional Impact
(6 items), Physical Functioning (9 items), Role Functioning (11 items),
Treatment Concern (3 items), and Worry (5 items).8–12 Higher scores
indicate better QOL.
2.5 Statistical analysis
Data were summarised using descriptive statistics. Regression analy-
ses using all FVIII samples were used to determine rate of change in
FVIII activity each year. Safety analyses included all infused partici-
pants. The6×1013 vg/kg cohort participant receivingon-demandFVIII
at baseline was not included in summaries of ABR and FVIII infusion
rate. Missing data were not imputed.
3 RESULTS
3.1 Participants
The studywas initiated June2015; the cutoff datewas29March, 2021.
Data include 5 years of follow-up for the 6 × 1013 vg/kg cohort and
4 years of follow-up for the 4× 1013 vg/kg cohort. Baseline participant
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characteristics were previously presented (Table S2).5,6 Prior to infu-
sion, bleeds requiring exogenous FVIII use occurred despite 12 of 13
participants being on a prophylactic FVIII regimen; baseline mean and
median ABR were 17.6 and 24.0, respectively, for the 6 × 1013 vg/kg
cohort and 12.2 and 8.0, respectively, for the 4 × 1013 vg/kg cohort. At
baseline, one participant in the 6× 1013 cohort and two in the 4× 1013
vg/kg cohort had at least three target joints.
3.2 Safety
Overall, the most common AEs associated with valoctocogene rox-
aparvovec were transient, asymptomatic, and mild-to-moderate ALT
elevations. Table 1 summarises AEs per year. In the past 2 years, no
unexpected safety events occurred (Table S3), and the overall safety
profile of valoctocogene roxaparvovec remains unchanged from previ-
ous reports.5,6 No participants experienced thrombotic events, devel-
oped FVIII inhibitors, or discontinued study participation.
No treatment-related serious AEs (SAEs) occurred beyond the sin-
gle event of Grade 2 pyrexia with myalgia and headache within 24 h
of infusion reported previously.5,6 In year 4, treatment-related AEs of
Grade 1 diarrhoea and Grade 1 hepatic steatosis were each reported
in a single 6 × 1013 vg/kg cohort participant. Hepatic steatosis was an
incidental liver ultrasound finding; this participant had a Grade 1 ALT
elevation during year 1 and normal liver function test results in other
years.
In the past 2 years, therewere three SAEs unrelated to treatment. A
manually ruptured furuncle bleed led to an overnight hospital stay for a
participant in the 6 × 1013 vg/kg cohort; his FVIII activity level was 9.9
IU/dl per CSA at the time of the event. In the 4× 1013 vg/kg cohort, one
participant had pre-existing severe chronic knee arthropathy neces-
sitating elective total knee replacement surgery, and one participant
reported a rectal haemorrhage due to an unrelatedmedical condition.
In the past 2 years, three additional participants reported asymp-
tomatic ALT elevations; none were deemed treatment-related by the
investigator. In the 6 × 1013 cohort, a participant reported an ALT ele-
vation 1.3-times the upper limit of normal (ULN) in year 5 that resolved
after 6 days and an ALT elevation 1.4-times ULN in year 4with no clear
causality that resolved after 43 days (next study visit). No glucocorti-
coidswere administered for either event. This participant had a history
of hepatitis C, which had cleared at enrolment. In year 3, a 4 × 1013
cohort participant reported anALTelevation2.1-timesULNassociated
with concomitant amoxicillin/clavulanate to treat an ear infection that
resolved without glucocorticoid treatment after 36 days (next study
visit); this participant had no history of liver disease. All events were
mild, transient, and asymptomatic, and none were associated with a
decrease in FVIII levels.
3.3 Efficacy
FVIII activity is shown in Figure 1. For participants in the 6 × 1013
cohort (n=7),mean (standarddeviation [SD]) andmedianFVIII activity
levels at the end of year 5 were 11.6 (12.2) and 8.2 IU/dl, respectively,
as measured by CSA and 18.7 (17.5) and 15.7 IU/dl, respectively, as
measured by OSA. At the end of year 4, mean (SD) and median FVIII
activity levels for participants in the 4 × 1013 cohort (n = 6) were 5.6
(5.6) and 4.8 IU/dl, respectively, per CSA and 9.5 (7.0) and 7.5 IU/dl,
respectively, per OSA (Table S4). As previously reported, OSA results
are approximately 1.6-times higher than CSA results; this ratio has
not changed over time.5,15 Regression analysis of each year (Figure 2)
shows that in both cohorts, FVIII activity rose to a peak in year 1 and
declined in the second year in proportion to peak FVIII expression,with
the lower peak in the 4 × 1013 vg/kg cohort associated with shallower
year-over-year declines. Beyond year 2, the slopes have become more
consistent and predictable with the 95% confidence interval (CI)
for each slope becoming narrower each year (Figure 2). The rate of
change in FVIII activity measured by CSA was -0.14 (95% CI, -.32 to
.03) IU/dl/wk in the 6 × 1013 vg/kg cohort in year 5 and -.06 (95% CI,
-.14 to .01) IU/dl/wk in the 4 × 1013 vg/kg cohort in year 4 (Figure 2).
The pattern of increasing consistency in the rate of FVIII activity
change over time is also apparent at the individual participant level
(Figure S1).
Participants in the 6 × 1013 vg/kg cohort on prophylaxis at base-
line (n = 6) had a mean (SD) ABR of 0.7 (1.6) treated bleeds/year dur-
ing year 5, resulting in a cumulative mean (SD) ABR of 0.8 (2.0) treated
bleeds/year from week 5 onward; this is a 95% reduction from base-
line (Figure 3A; Table S5). Participants in the 4× 1013 vg/kg cohort had
a mean (SD) ABR of 1.7 (2.3) treated bleeds/year during year 4, result-
ing in a cumulativemean (SD)ABRof 1.0 (1.9) treated bleeds/year from
week 5 onward, a 92% reduction from baseline.
For participants in the 6 × 1013 vg/kg cohort receiving prophylaxis
at baseline (n = 6), the mean annualised rate of FVIII infusion was 5.5
infusions/year in year 5, a 96% cumulative reduction from baseline.
For participants in the 4 × 1013 vg/kg cohort, year 4 annualised FVIII
infusion rate was 7.8 infusions/year, a cumulative 95% reduction from
baseline (Figure 3B). All participants in the 4× 1013 and 6× 1013 vg/kg
cohorts continue to remain off FVIII prophylaxis.
Individual participant ABRs and annualised FVIII usage before and
after infusion are shown in Figure 4, along with their FVIII range at the
endof year 5 (6×1013 vg/kg cohort) and year 4 (4×1013 vg/kg cohort).
At last analysis, four of seven and three of six participants in the 6 ×
1013 and4×1013 vg/kg cohorts, respectively,maintainedmedian FVIII
levels>5 IU/dl, corresponding tomild haemophilia.
In the6×1013 cohort, five of sevenparticipants reportedno treated
bleeds in either year 4 or 5. Participant six reported eight bleeds during
year 4: five spontaneous bleeds in prior target joints and three trau-
matic non-joint bleeds (two after falling down stairs, one finger bleed
occurred at work); and four bleeds during year 5: one spontaneous
bleed in prior target joint, and three traumatic non-joint bleeds (one
from pulled lower back muscle, one from stubbed toe, and one from
knocking his hand). At week 260, participant six’s FVIII activity was 3.3
IU/dl. Comparedwith his baseline ABR of 24 treated bleeds/year while
on prophylaxis, his bleeding rate decreased by 79% following treat-
ment with valoctocogene roxaparvovec. Participant four reported the
SAE of traumatic bleeding due tomanual rupture of a furuncle.
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4x1013 vg/kg FVIII activity 6x1013 vg/kg FVIII activity
Mean 5.6 by CSA (9.5 by OSA)
Median 4.8 by CSA (7.5 by OSA)
Mean 11.6 by CSA (18.7 by OSA)
Median 8.2 by CSA (15.7 by OSA)
F IGURE 1 FVIII activity measured by the chromogenic substrate assay for participants in the 6× 1013 and 4× 1013 vg/kg cohorts over 5 and 4
years, respectively. FVIII activity levels takenwithin 72 h of exogenous FVIII administration were excluded. FVIII activity that fell below the lower
limit of quantitation (<3.0 IU/dl) was imputed as 0 IU/dl.Whiskers represent theminimum andmaximum values; boxes represent the 25th and




























L) Year 1          
Year 2          
Year 3          
Year 4
Year 5
6x1013 vg/kg cohort (n=7)
0 50 100 150 200 250
Y1 Y2 Y3 Y4 Y5
0.140.270.150.241.01Slope, IU/dL/wk


























L) Year 1          
Year 2          
Year 3          
Year 4
4x1013 vg/kg cohort (n=6)
0 50 100 150 200
Week
Y1 Y2 Y3 Y4
0.060.080.150.35Slope, IU/dL/wk
0.14, 0.010. 7, 0.020.37, 0.070.01, 0.7195% CI
(A) (B)
F IGURE 2 FVIII activity measured by the chromogenic substrate assay and regression for all samples. (A) Participants in the 6× 1013 vg/kg
cohort over 5 years, and (B) participants in the 4× 1013 vg/kg cohort over 4 years. FVIII activity levels takenwithin 72 h of exogenous FVIII
administration were excluded. FVIII activity that fell below the lower limit of quantitation (<3 IU/dl) was imputed as 0 IU/dl. FVIII, factor VIII
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Annualised FVIII infusion rate
(infusions/year)
6x1013 vg/kg cohort (n = 6)
4x1013 vg/kg cohort (n = 6)
A)
B)
F IGURE 3 Pre- and postinfusion of valoctocogene roxaparvovec annualised rates of bleeding and FVIII infusion. (A) Annualised rates of
bleeding and FVIII infusion for the 6× 1013 vg/kg cohort at baseline and in years 1, 2, 3, 4, and 5. (B) Annualised rates of bleeding and FVIII infusion
for the 4× 1013 vg/kg cohort at baseline and in years 1, 2, 3, and 4. The participant in the 6× 1013 cohort receiving on-demand FVIII treatment at
baseline was excluded. Year 1 includedweeks 5–52 only; Year 2 includedweeks 53–104; Year 3 includedweeks 105–156; Year 4 includedweeks
157–208; Year 5 includedweeks 209–260. †In year 5, in addition to treatment for bleeding, two participants in the 6× 1013 vg/kg cohort had 12
instances of exogenous FVIII use due to surgery. ‡In year 4, in addition to treatment for bleeding, two participants in the 6× 1013 vg/kg cohort had
two instances of exogenous FVIII use due to surgery. §In year 3, in addition to treatment for bleeding, one participant in the 6× 1013 vg/kg cohort
had 23 instances of exogenous FVIII use due to surgery, including knee replacement. ¶In year 2, in addition to treatment for bleeding, two
participants in the 6× 1013 vg/kg cohort had 48 instances of exogenous FVIII use due to surgery. ††In year 1, in addition to treatment for bleeding,
no participants in the 6× 1013 vg/kg cohort used exogenous FVIII as prophylaxis for surgery. ‡‡In year 4, in addition to treatment for bleeding, one
participant in the 4× 1013 vg/kg cohort had three instances of FVIII use due to surgery, including colonoscopy with biopsy. §§In year 3, in addition
to treatment for bleeding, three participants in the 4× 1013 vg/kg cohort had 46 instances of exogenous FVIII use due to surgery, including knee
replacement and liver biopsy. ¶¶In year 2, in addition to treatment for bleeding, one participant in the 4× 1013 vg/kg cohort had one instance of
exogenous FVIII use due to sigmoidoscopy. †††In year 1, in addition to treatment for bleeding, one participant in the 4× 1013 vg/kg cohort had one
instance of exogenous FVIII use due to surgery. FVIII, factor VIII
In the 4 × 1013 cohort, three of six participants reported no treated
bleeds in either year 3or 4. Participant 10 reported four traumatic non-
target joint bleeds (one occurred after jumping from a bridge into a
boat, one after playing football, one at the gym, and one from punching
a punching bag). In the year prior to enrolment, participant 10 experi-
enced one treated bleed per year. At weeks 134 and 174, around the
time of these bleeds, participant 10 had an FVIII activity level of 10.5
and 9.5 IU/dl, respectively. Participant 15 reported nine bleeds: three
spontaneous bleeds in prior target joints, three traumatic bleeds from
prolonged standing at work, and three of unknown causality. At week
208, participant 15hadFVIII activity levels<3 IU/dl (LLOQofCSA). His
bleeding rate was reduced by 63% from his baseline ABR of 12 treated
bleeds/year while on prophylaxis. Participant 12 reported one bleed of
unknown causality as well as the SAE of rectal haemorrhage related to
Crohn’s disease. At baseline, his ABRwas zero treated bleeds/year, and
fromweek 168 onward his FVIII activity was<3.0 IU/dl.
During the past 2 years, most exogenous FVIII use was one-time
prophylaxis for procedures, including dental surgery, intra-articular
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F IGURE 4 Individual participants’ annualised FVIII infusion rate and ABR at baseline and fromweek 5 and onward and FVIII activity at the end
of year 5 or 4. (A) The 6× 1013 vg/kg cohort. (B) The 4× 1013 vg/kg cohort. Participants are ordered by descending current FVIII activity (week
260 for 6× 1013 cohort; week 208 for 4× 1013 cohort). Current FVIII activity ranges are based onmedian value in a±4-weekwindow. †Fromweek
5 onward, participant nine had one instance of exogenous FVIII use for surgery prophylaxis. ‡Fromweek 5 onward, in addition to treatment for
bleeding, participant four had four instances of exogenous FVIII use due to prophylaxis for surgery and liver biopsy. §Fromweek 5 onward, in
addition to treatment for bleeding, participant six had 47 instances of exogenous FVIII use due to surgery prophylaxis, including total knee
replacement. ¶Fromweek 5 onward, participant three had 34 instances of exogenous FVIII use due to prophylaxis for total knee replacement
surgery and liver biopsy. ††Fromweek 5 onward, in addition to treatment for bleeding, participant 11 had two instances of exogenous FVIII use due
to liver biopsy. ‡‡Fromweek 5 onward, participant 14 only used exogenous FVIII as treatment for bleeding. §§Fromweek 5 onward, in addition to
treatment for bleeding, participant 10 had one instance of exogenous FVIII use due to prophylaxis for a sigmoidoscopy. ¶¶Fromweek 5 onward, in
addition to treatment for bleeding, participant 12 had three instances of exogenous FVIII use due to prophylaxis for procedures, including
colonoscopy with biopsies taken. †††Fromweek 5 onward, in addition to treatment for bleeding, participant 13 had three instances of exogenous
FVIII use due to prophylaxis for surgery, a tooth extraction, and steroid injection. ‡‡‡Fromweek 5 onward, in addition to treatment for bleeding,
participant 15 had 43 instances of exogenous FVIII use due to general surgery, total knee replacement, and liver biopsy. ABR, annualised bleeding
rate; CS, chromogenic substrate assay; FVIII, factor VIII; LLOQ, lower limit of quantitation; OS, one-stage assay; SAE, serious adverse event.
[Correction added on 28August 2021, after first online publication: In Figure 4, the values for Participants 3 and 13werewrongly aligned and have
been corrected in this version.]
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F IGURE 5 Haemo-QOL-A Total Score over 5 years. Dotted lines indicate baseline values for each cohort. Total score is based on six domains:
Consequences of Bleeding (7 items), Emotional Impact (6 items), Physical Functioning (9 items), Role Functioning (11 items), Treatment Concern (3
items), andWorry (5 items). Haemo-QOL-A, haemophilia-specific health-relatedQOL questionnaire for adults; SD, standard deviation
glucocorticoid injections, gastroscopy, and biopsies. Participant 15
received prophylactic FVIII treatments following total knee replace-
ment surgery. As noted previously, participants four, six, 10, 12, and 15
received FVIII treatment for their bleeding events. Over all 5 years of
follow-up, two participants in the 6 × 1013 vg/kg cohort (participants
four and nine) had five procedures or surgeries, including fluoroscopy-
guided steroid injection and dental extraction, without prior FVIII pro-
phylaxis. At the time of these procedures, FVIII levels were in the mild
haemophilia range by CSA.
3.4 Quality of life
At baseline, participants in the 6 × 1013 vg/kg cohort had a total
Haemo-QOL-A score of 71.9 (16.6), which increased by a mean (SD)
of 10.3 (13.6) to 82.2 (18.1) at the end of year 5 (n = 7) (Figure 5 and
Figure S2). Participants in the 4×1013 vg/kg cohort had a high baseline
mean (SD) total Haemo-QOL-A score of 80.8 (9.1), which was main-
tained over time. At the end of year 4, mean (SD) total Haemo-QOL-A
scorewas 80.3 (10.4) for the 4× 1013 vg/kg cohort (n= 5). On average,
all 6 domains of the Haemo-QOL-A improved relative to baseline
in participants in the 6 × 1013 vg/kg cohort. In the 4 × 1013 vg/kg
cohort, three domains (Role Functioning [mean change from baseline,
1.82], Treatment Concern [5.33], and Worry [8.8]) improved from
baseline on average, while the others did not change (Consequences
of Bleeding [0]) or decreased slightly (Emotional Impact [-2.0] and
Physical Functioning, [-4.4]).
4 DISCUSSION
These results represent the longest durationof follow-up fromanyclin-
ical gene therapy study for severe haemophilia A. Safety, efficacy, and
QOL results for up to 5 years are presented for participants following
a single dose of valoctocogene roxaparvovec. These data demon-
strate continued clinical benefit and an acceptable safety profile, and
maintenance of increasedQOL from baseline or high baseline QOL.
Five years postinfusion, safety results were aligned with previous
observations, showing no unexpected new safety signals.5,6 No partici-
pants developedFVIII inhibitors. Previously observed liver enzymeele-
vations had no apparent sequelae, thoughmild liver damage cannot be
ruled out without biopsy evidence. In the past 2 years of follow-up, one
participant in the6×1013 cohort reported twoALTelevations, andone
participant in the 4 × 1013 vg/kg cohort reported one ALT elevation.
None impacted FVIII expression and all resolved without glucocorti-
coid treatment. The lengthy temporal separation between these ALT
elevations and those in the first year post-gene therapy suggests they
were separate events.
Efficacy at 5 years postinfusion in the 6 × 1013 vg/kg cohort was
similar to that observed at 3 years, as assessed by treated ABR and
exogenous FVIII utilisation.5,6 All 13 participants in both cohorts con-
tinued to experience substantial reductions in ABR compared to base-
line. All participants, including those who had relatively low FVIII
activity levels, remain off prophylaxis. After 5 years of follow-up,
observed clinical effects align with other gene therapy trials and the
natural history of the disease in that even low levels of endoge-
nously expressed clotting factors can ameliorate the haemophilic
phenotype.16–18
FVIII activity is reported based on both CSA and OSA. Recent work
demonstrates that the CSAmore closely estimates the specific activity
of the transgene-produced FVIII protein, due to kinetic differences in
Factor Xa and thrombin formation by transgenic FVIII-SQ15; however,
investigation in a larger dataset is required to determine the clinical
haemostatic predictiveness of either assay. At most recent measure-
ment, 10 out of 13 participants continued to have FVIII levels above
the severe haemophilia range (<1 IU/dl) per CSA, while three partici-
pants had FVIII levels below the CSA LLOQ (<3 IU/dl). Of seven partic-
ipants in the 6 × 1013 vg/kg cohort, two had FVIII activity levels cor-
responding to moderate haemophilia (3–5 IU/dl) and four were in the
mild haemophilia range (>5–40 IU/dl) at year 5. Of six participants in
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the 4 × 1013 vg/kg cohort, one had FVIII activity levels correspond-
ing to moderate haemophilia and three had FVIII activity correspond-
ing to mild haemophilia at year 4. A regression analysis of the rate
of FVIII activity change provides insight into the trajectory over time
and reveals increasing consistency and predictability of that trajectory,
both between andwithin participants, in the recent years of this study.
Our data also suggest clinical benefits of sustained FVIII lev-
els, without frequent prophylactic intravenous infusions, may be
associated with improved QOL. The existence of a disability para-
dox in haemophilia indicates general health questionnaires such as
the EuroQol-5D-5L may underestimate haemophilia-related QOL
burdens.19 Thehaemophilia-specificHaemo-QOL-Ahasdemonstrated
robust validity among adults undergoing standard treatment for
haemophilia,9,10,20,21 and a change in Haemo-QOL-A Total Score of
approximately seven is considered meaningful in that population.22,23
QOL scores in the 6 × 1013 vg/kg cohort increased by>7 over 5 years.
TheseQOL improvements are in addition to benefits derived frompro-
phylaxis, as all but one participantwere on prophylaxis at baseline.10,24
In the4×1013 vg/kg cohort, highbaseline scoresweremaintained, per-
haps reflecting a ceiling effect. However, the Haemo-QOL-A was not
developed for use with gene therapy and may therefore not fully cap-
ture its impact onQOL.Work is ongoing to validate theHaemo-QOL-A
in this context to ascertain the clinically important difference in total
score.25
Limitations of this study include the small sample size and open-
label trial design, which may weaken QOL data interpretability.
Participants with the highest unmet need in terms of high baseline
bleeding ratesmay also have beenmostmotivated to enrol. High intra-
and interparticipant variability, particularly notable during the first
couple of years after treatment, are likely due to the large number of
molecular events that must occur for AAV-mediated gene therapy to
result in predictable FVIII protein production.26 However, the exact
mechanisms underlying individual participant variation in FVIII and
observed declines in FVIII over time are not yet known. Additional
basic research is underway, and further clinical studies with larger
sample sizes may elucidate contributors to variability and suggest
minimisation or management strategies.
5 CONCLUSION
These results demonstrate that valoctocogene roxaparvovec gene
therapy can lead to reductions from baseline ABR and FVIII utilisation
in people with severe haemophilia A. Haemostatic efficacy was largely
maintained in these two dose groups over 4 and 5 years, and the
safety profile remained acceptable. Average participant QOL was
improved or maintained from baseline. Gene therapy could repre-
sent a paradigm shift in the treatment of haemophilia A, enabling
long-lasting treatment and improving clinical and patient-centred
outcomes, including QOL. A phase 3 clinical trial (NCT03370913)
of valoctocogene roxaparvovec is currently assessing these
possibilities.
ACKNOWLEGEMENTS
Funding for this studywas providedbyBioMarinPharmaceutical.Med-
ical writing and editorial support were provided by Kathleen Pieper,
PhD; and Atreju Lackey, PhD, of AlphaBioCom, LLC, and funded by
BioMarin Pharmaceutical. We thank all the study participants and
study site personnel: Stefan Tiefenbacher and Mary Robinson, of Eso-
terix, for factor VIII assays and consulting; and the following employ-
ees of BioMarin Pharmaceutical: Jennifer Quinn for Haemo-QOL-
A data interpretation; Brian Long for immunogenicity assessments;
Kala Jayaram for safety assessments; Mingjin Li for statistical anal-
yses; Joshua Henshaw for peripheral blood analyses and interpreta-
tion; Steve Zoog and Christian Vettermann for assistance with bioana-
lytic strategy, assay design and validation, and data interpretation; and
Kendra Bolt, Sara Hawley, and Micah Robinson for writing and project
management support.
CONFLICTS OF INTEREST
K John Pasi is an employee for Roche and reports receiving consulting
payments from Alnylam, APCintex, BioMarin, Bioverativ, Catalyst Bio,
Catapult, Chugai, Roche, Novo Nordisk, Sanofi, and Sobi; participating
as a clinical trial investigator for BioMarin, Sanofi, and UniQure;
receiving speaker fees from Bayer, BioMarin, Biotest, Novo Nordisk,
Sanofi, Shire, Sobi, Octapharma, Pfizer, and UniQure; and receiv-
ing travel support from Alnylam, Bayer, BioMarin, Bioverativ, Novo
Nordisk, Octapharma, Pfizer, Sobi, Sanofi, and Shire. Michael Laffan
reports receiving grants fromBioMarin; personal fees fromBayer, LEO
Pharma, LFB Biopharmaceuticals, Pfizer, Roche, Shire, and Sobi; and
travel support from Bayer, LFB Biopharmaceuticals, and Sobi. Savita
Rangarajan reports receiving grants from Roche and Sangamo; travel
support from Reliance Life Sciences and Shire/Takeda; and consulting
payments from Pfizer, Reliance Life Sciences, Sanofi, and Shire/Takeda.
Will Lester reports receiving grants from BioMarin; personal fees
from Bayer, LFB, Novo Nordisk, Sobi, and Takeda; and travel support
from Takeda and CSL. Emily Symington reports receiving grants from
BioMarin and travel support fromCSLBehring andNovoNordisk. Bella
Madan reports nothing to disclose. NinaMitchell is a former employee
of BioMarin Pharmaceutical and may own stock. Tara M. Robinson,
Xinqun Yang, Benjamin Kim, and Wing Yen Wong are employees
and stockholders of BioMarin Pharmaceutical. Glenn F. Pierce is an
employee of Voyager Therapeutics; reports receiving consulting pay-
ments from Ambys Medicines, BioMarin Pharmaceutical, BridgeBio,
CRISPR Therapeutics, Decibel Therapeutics, Frontera, Generation
Bio, Geneception, Novo Nordisk, Pfizer, Regeneron, Spark, and Third
Rock Ventures; and is a board member of the World Federation
of Haemophilia, Voyager Therapeutics, Global Blood Therapeutics,
VarmX, and the Medical and Scientific Advisory Council of the US
National Haemophilia Foundation.
AUTHOR CONTRIBUTIONS
K John Pasi, Glenn F Pierce, and Wing Yen Wong contributed to con-
ception and design of the study. K John Pasi, Savita Rangarajan, Will
Lester, Emily Symington, Bella Madan, and Michael Laffan carried out
956 PASI ET AL.
the clinical study. Benjamin Kim, Tara M. Robinson, Nina Mitchell, and
Wing Yen Wong oversaw the conduct of the study; Tara M. Robinson
and Nina Mitchell were the medical monitors. Xinqun Yang performed
the statistical and data analyses. All authors critically reviewed the
manuscript, provided input on data interpretation, and approved the
final draft for submission.
DATA AVAILABIITY STATEMENT
De-identified individual participant data underlying these results will
be made available together with the clinical protocol and data dictio-
naries, for noncommercial, academic purposes. Additional supporting
documents may be available upon request. Investigators will be able to
request access to these data and supporting documents via the Publi-
cation Data Request page at www.BioMarin.com beginning 6 months
and ending 2 years after publication. Data associated with any ongo-
ing development programwill be made available within 6months after
approval of the relevant product. Requests must include a research
proposal clarifying how thedatawill be used, including proposed analy-
sis methodology. Research proposals will be evaluated relative to pub-
licly available criteria available at www.BioMarin.com to determine if
access will be given, contingent upon execution of a data access agree-
ment with BioMarin Pharmaceutical Inc.
REFERENCES
1. Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the
management of hemophilia, 3rd edition. Haemophilia. 2020;26(6):1-
158.
2. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for
themanagement of hemophilia.Haemophilia. 2013;19(1):e1-47.
3. MazepaMA,Monahan PE, Baker JR, et al.Menwith severe hemophilia
in the United States: birth cohort analysis of a large national database.
Blood. 2016;127(24):3073-3081.
4. Kruse-Jarres R, Oldenburg J, Santagostino E, et al. Bleeding and safety
outcomes in persons with haemophilia A without inhibitors: results
from a prospective non-interventional study in a real-world setting.
Haemophilia. 2019;25(2):213-220.
5. Rangarajan S, Walsh L, Lester W, et al. AAV5-factor VIII gene transfer
in severe hemophilia A.N Engl J Med. 2017;377(26):2519-2530.
6. Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear follow-up of
AAV5-hFVIII-SQ gene therapy for hemophilia A. N Engl J Med.
2020;382(1):29-40.
7. Bunting S, Zhang L, Xie L, et al. Gene therapy with BMN 270 results in
therapeutic levels of FVIII in mice and primates and normalization of
bleeding in hemophilic mice.Mol Ther. 2018;26(2):496-509.
8. Rentz A, Flood E, Altisent C, et al. Cross-cultural development and
psychometric evaluation of a patient-reported health-related qual-
ity of life questionnaire for adults with haemophilia. Haemophilia.
2008;14(5):1023-1034.
9. Sun HL, Mcintosh KA, Squire SJ, et al. Patient powered prophylaxis:
a 12-month study of individualized prophylaxis in adults with severe
haemophilia A.Haemophilia. 2017;23(6):877-883.
10. Manco-Johnson MJ, Lundin B, et al. Effect of late prophylaxis in
hemophilia on joint status: a randomized trial. J Thromb Haemost.
2017;15(11):2115-2124.
11. Stemberger M, Kallenbach F, Schmit E, et al. Impact of adopting
population pharmacokinetics for tailoring prophylaxis in haemophilia
A patients: a historically controlled observational study. Thromb
Haemost. 2019;119(3):368-376.
12. St-Louis J, Urajnik DJ, Menard F, et al. Generic and disease-specific
quality of life among youth and youngmenwithHemophilia in Canada.
BMCHematol. 2016;16.
13. Protocol for: Rangarajan S, Walsh L, Lester W, et al. AAV5–factor VIII
gene transfer in severe hemophilia A. N Engl J Med. 2017;377:2519-
2530.
14. Kotin RM, Snyder RO. Manufacturing clinical grade recombinant
adeno-associated virus using invertebrate cell lines. Hum Gene Ther.
2017;28(4):350-360.
15. Rosen S, Tiefenbacher S, Robinson M, et al. Activity of transgene-
produced B-domain-deleted factor VIII in human plasma following
AAV5 gene therapy. Blood. 2020;136(22):2524-2534.
16. Nathwani AC, Reiss UM, Tuddenham EGD, et al. Long-term safety
and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med.
2014;371(21):1994-2004.
17. Nathwani AC, Tuddenham EGD, Rangarajan S, et al. Adenovirus-
associated virus vector-mediated gene transfer in hemophilia B.NEngl
J Med. 2011;365(25):2357-2365.
18. Den Uijl IEM, Fischer K, Van Der Bom JG, et al. Analysis of low fre-
quency bleeding data: the association of joint bleeds according to
baseline FVIII activity levels.Haemophilia. 2011;17(1):41-44.
19. O’hara J, Martin AP, Nugent D, et al. Evidence of a disability
paradox in patient-reported outcomes in haemophilia. Haemophilia.
2021;27(2):245-252.
20. Limperg PF, Terwee CB, Young NL, et al. Health-related quality of life
questionnaires in individuals with haemophilia: a systematic review
of their measurement properties. Haemophilia. 2017;23(4):497-
510.
21. Wharfe G, Buchner-Daley L, Gibson T, et al. The Jamaican
Haemophilia Registry: describing the burden of disease. Haemophilia.
2018;24(4):e179-e186.
22. WyrwichKW,KrishnanS, Poon JL, et al. Interpreting important health-
related quality of life change using the Haem-A-QoL. Haemophilia.
2015;21(5):578-584.
23. Santagostino E, Lentz SR, Busk AK, et al. Assessment of the impact of
treatment on quality of life of patients with haemophilia A at different
ages: insights from two clinical trials on turoctocog alfa. Haemophilia.
2014;20(4):527-534.
24. UsubaK, PriceVE, BlanchetteV, et al. Impact of prophylaxis on health-
related quality of life of boys with hemophilia: an analysis of pooled
data from 9 countries. Res Pract Thromb Haemost. 2019;3(3):397-
404.
25. Quinn J,MitchellN&WongWYClinical Validation of theHaemo-QoL-
AQuestionnaire in Adults with Severe Hemophilia A Treatedwith Val-
octocogeneRoxaparvovec: Results from2Studies. Abstract presented
at Hemophilia Federation of America Symposium. 2020.
26. Pierce GF. Uncertainty in an era of transformative therapy for
haemophilia: addressing the unknowns.Haemophilia. 2021;27(3):103-
113.
SUPPORTING INFORMATION
Additional supporting informationmay be found online in the Support-
ing Information section at the end of the article.
How to cite this article: Pasi KJ, LaffanM, Rangarajan S, et al.
Persistence of haemostatic response following gene therapy
with valoctocogene roxaparvovec in severe haemophilia A.
Haemophilia. 2021;27:947–956.
https://doi.org/10.1111/hae.14391
